APLS Q2 2019 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$63M

Operating Income

-$63M

Net Income

-$71M

EPS (Diluted)

$-1.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$317M

Total Liabilities

$158M

Stockholders' Equity

$159M

Cash & Equivalents

$289M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$63M	-$33M	-89.6%
Operating Income	-$63M	-$33M	-89.6%
Net Income	-$71M	-$33M	-113.3%